Arrowhead price target lowered to $78 from $81 at Morgan Stanley

Group 1 - Morgan Stanley has lowered the price target on Arrowhead (ARWR) to $78 from $81 while maintaining an Equal Weight rating on the shares [1] - The firm anticipates continued broad pipeline execution with multiple readouts expected later this year, including key Phase 3 SHTG data in Q3 [1] - Early trends in the launch of familial chylomicronemia syndrome are promising, but meaningful sales are not expected until 2026 [1]